Target levels of functional C1‐inhibitor in hereditary angioedema

To cite this article: Hack CE, Relan A, van Amersfoort ES, Cicardi M. Target levels of functional C1‐inhibitor in hereditary angioedema. Allergy 2012; 67: 123–130.

[1]  B. Chipps.  Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema , 2011, Pediatrics.

[2]  T. Klingebiel,et al.  Pharmacokinetic Berinert P Study Of Subcutaneous Versus Intravenous Administration In Subjects With Moderate Hereditary Angioedema - The Passion Study , 2011 .

[3]  J. Nuijens,et al.  Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. , 2010, The Journal of allergy and clinical immunology.

[4]  A. Sheffer,et al.  Ecallantide for the treatment of acute attacks in hereditary angioedema. , 2010, The New England journal of medicine.

[5]  William H. Yang,et al.  Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. , 2010, The New England journal of medicine.

[6]  J. Bernstein,et al.  Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[7]  T. Klingebiel,et al.  Pharmacokinetic analysis of human plasma–derived pasteurized C1‐inhibitor concentrate in adults and children with hereditary angioedema: a prospective study , 2010, Transfusion.

[8]  A. Kaplan,et al.  Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[9]  A. Bygum,et al.  Hereditary angio‐oedema in Denmark: a nationwide survey , 2009, The British journal of dermatology.

[10]  J. Bernstein,et al.  Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. , 2009, The Journal of allergy and clinical immunology.

[11]  T. Klingebiel,et al.  C1‐inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis , 2009, Transfusion.

[12]  M. Gobbi,et al.  Recombinant C1 inhibitor in brain ischemic injury , 2009, Annals of neurology.

[13]  N. Marzella,et al.  Cinryze, a human plasma-derived c1 esterase inhibitor for prophylaxis of hereditary angioedema. , 2009, P & T : a peer-reviewed journal for formulary management.

[14]  B. Zuraw.  Clinical practice. Hereditary angioedema. , 2008, The New England journal of medicine.

[15]  H. Farkas,et al.  Recombinant human C1‐inhibitor in the treatment of acute angioedema attacks , 2007, Transfusion.

[16]  S. Cichon,et al.  Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. , 2006, American journal of human genetics.

[17]  K. Bork,et al.  Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. , 2006, Biochemical and biophysical research communications.

[18]  A. Eerenberg,et al.  A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. , 2005, The Journal of allergy and clinical immunology.

[19]  J. Alsenz,et al.  The critical concentration of C1-esterase inhibitor (C1-INH) in human serum preventing auto-activation of the first component of complement (C1). , 2005, Molecular immunology.

[20]  R. Bayer,et al.  Production of a complement inhibitor possessing sialyl Lewis X moieties by in vitro glycosylation technology. , 2004, Glycobiology.

[21]  J. Kamerling,et al.  N- and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits. , 2003, Glycobiology.

[22]  K. Kragballe,et al.  Hereditary Angioedema. , 2018, The New England journal of medicine.

[23]  M. Cicardi,et al.  Bradykinin-mediated angioedema. , 2002, The New England journal of medicine.

[24]  M. Blajchman,et al.  The Clearance of Thrombin-antithrombin and Related Serpin-enzyme Complexes from the Circulation: Role of Various Hepatocyte Receptors , 1999, Thrombosis and Haemostasis.

[25]  M. Cicardi,et al.  Plasma bradykinin in angio-oedema , 1998, The Lancet.

[26]  F. Rosen,et al.  A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema , 1998, Transfusion.

[27]  F. Rosen,et al.  Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. , 1996, The New England journal of medicine.

[28]  J. Bissler,et al.  Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443-->Val substitution and functional analysis of the recombinant mutant protein. , 1995, The Journal of clinical investigation.

[29]  A. Eerenberg,et al.  Generation of plasmin during acute attacks of hereditary angioedema. , 1993, The Journal of laboratory and clinical medicine.

[30]  E. Hack,et al.  Plasma levels of C1- inhibitor complexes and cleaved C1- inhibitor in patients with hereditary angioneurotic edema. , 1990, The Journal of clinical investigation.

[31]  B. Wüthrich,et al.  Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema--evidence of a functionally critical level of C1-inhibitor concentration. , 1984, Complement.

[32]  R. Colman,et al.  Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. , 1983, The New England journal of medicine.

[33]  R. Ziccardi.  A new role for C-1-inhibitor in homeostasis: control of activation of the first component of human complement. , 1982, Journal of immunology.